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In light of the COVID-19 pandemic, on March 24, the American 
Society of Plastic Surgeons (ASPS) issued guidelines on how to triage 
breast reconstruction.1 At the time of this commentary, the current 
guidelines from the ASPS recommend “caution and [to] delay recon-
struction” and that because it is elective, “immediate autologous flap 
reconstruction for breast reconstruction…should be delayed.” It also 
recommends that “while erring on the side of delayed reconstruction, 
immediate tissue expander or direct to implant reconstruction can be 
evaluated on a case-by-case basis.” These guidelines echo statements 
issued by the American College of Surgeons (ACS) that “autolo-
gous breast reconstruction should be deferred,” and by the Society of 
Surgical Oncology (SSO) that breast reconstruction “should enable 
recovery as an outpatient.”2,3
In settings where reconstruction is not feasible because of a lack 
of personal protective equipment, reduction in available operating 
rooms, and limitations in staffing, it is certainly appropriate to delay 
breast reconstruction. However, when possible, immediate recon-
struction should be performed because it has been shown to result in 
better psychosocial outcomes compared to delayed reconstruction.4 
Immediate reconstruction also avoids the perioperative risks of gen-
eral anesthesia associated with a second operation and additional 
out-of-pocket expenses that can occur from an insurance standpoint 
when breast reconstruction is delayed. From a plastic surgery per-
spective, immediate reconstruction enables maximal preservation of 
the native skin envelope and optimizes breast shape and symmetry.
Upon cursory consideration, restriction of immediate autologous 
reconstruction in favor of delayed autologous reconstruction or im-
mediate implant-based reconstruction during the pandemic may 
seem prudent. With the goal of minimizing the duration of operative 
room times to conserve resources, implant-based reconstruction 
adds less time to the mastectomy operation and utilizes fewer intra-
operative resources compared to autologous reconstruction. In con-
trast, autologous reconstruction requires specialized instruments, 
equipment, and experienced team members with microsurgery ex-
pertise to facilitate efficient operative flow. Furthermore, the typical 
postoperative inpatient stay for autologous reconstruction is ap-
proximately three nights compared to implant-based reconstruction 
which can often be performed on an outpatient basis. Autologous 
reconstruction also mandates dedicated nursing staff to monitor 
the free flap during the hospital stay. These added resources, time, 
and labor requirements are balanced by the fact that autologous re-
construction results in higher patient satisfaction and psychosocial 
well-being compared to implant-based reconstruction.5
As many hospital systems and multi-disciplinary breast care 
teams rely on national guidelines to direct the practice of breast 
reconstruction during the pandemic, it is important to consider the 
immediate and long-term implications of broadly recommending im-
plant-based breast reconstruction in the setting of COVID-19. In a 
recent study of over 12 000 women, implant-based reconstruction 
was associated with a greater number of hospital admissions and 
office visits compared to autologous reconstructions over a 2-year 
period.6 While the mean inpatient hospital stay for autologous re-
construction was 3.6 days compared to 1.9 for implant-based re-
construction, subsequent inpatient admissions over a 2-year period 
were about 15% greater in the implant group compared to the autol-
ogous group. Moreover, a relatively common indication for hospital 
admission after implant-based reconstruction is postoperative infec-
tion, which can involve several days of receiving intravenous antibi-
otics. If this is unsuccessful, an operation to remove and potentially 
exchange the implant is recommended. Particularly in this context, 
the current breast reconstruction guidelines, which assume that 
 implant-based reconstruction is a far less risky and less complicated 
option compared to autologous reconstruction, do not necessarily 
reflect a truly evidence-based comparison of breast reconstruction 
options. Furthermore, in relation to the conservation initiatives re-
sulting from COVID-19, it may be a misconception that implant-based 
reconstruction is associated with substantially less resource and 
personnel utilization compared to autologous reconstruction.
Another implication of implant-based reconstruction, specif-
ically tissue expander reconstruction, is the need for serial filling 
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that is typically performed on a weekly basis by clinic staff. In their 
study, Lemaine et al discovered that implant-based reconstruction 
was associated with more office visits compared to autologous re-
construction.6 This frequent need for travel is concerning given 
the importance of social distancing in preventing the spread of the 
coronavirus. For example, a recent study from the Harvard School 
of Public Health found a link between infection rates in neighbor-
hoods in New York City with a high prevalence of the COVID-19 
disease, and the number of trips taken by its residents into and out 
of the neighborhood.7 From a public health standpoint, this has sig-
nificant implications when performing tissue expander reconstruc-
tion because women who need to undergo weekly expansions will 
interact with at least one health care provider each time. For women 
commuting, and for family members commuting with patients, these 
multiple trips increase the risk of contracting COVID-19. In addition, 
for women with tissue expanders who cannot commute because of 
various restrictions, the process of reconstruction is stalled for an 
indeterminate period of time, which may result in unnecessary psy-
chological harm.
We believe that both implant-based and autologous breast re-
construction are important for women after mastectomy and that 
the ultimate decision regarding which approach to pursue should 
be made between the patient and plastic surgeon. In the setting of 
the COVID-19 pandemic, it is the plastic surgeon's responsibility to 
provide breast reconstruction without placing undue burden on the 
health care system or risk to the patient. While the current national 
guidelines are helpful, they appear to unfairly restrict autologous re-
construction without bearing in mind the implications of potential 
complications associated with implant-based reconstruction, such as 
hospital readmissions for infection, additional surgery, and in-person 
clinic visits.
Organizations such as the ASPS, ACS, and SSO provided timely 
guidance during the onset of the COVID-19 pandemic. However, 
with the pandemic entering into a new phase, there is a need to issue 
updated guidelines that reflect the available evidence supporting the 
importance of breast reconstruction while simultaneously promot-
ing resource conservation and safe public health practices that min-
imize the risk of coronavirus transmission. Without these important 
changes to the national recommendations, some patients who would 
otherwise choose autologous reconstruction will face the difficult 
decision and consequences of either forgoing any immediate recon-
struction after mastectomy or reluctantly undergoing implant-based 
reconstruction.
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